Connect with us

International

Blending Data and Real Estate

Blending data and real estate cause misnomers everywhere. Examples of misnaming abound. Panama hats actually come from Ecuador, French horns originated in Germany, not France, and pencil lead is not made of lead, but graphite. Similarly, while the name…

Published

on

Blending data and real estate cause misnomers everywhere.

Examples of misnaming abound. Panama hats actually come from Ecuador, French horns originated in Germany, not France, and pencil lead is not made of lead, but graphite.

Similarly, while the name “real estate investment trusts” (REITs) seems to indicate that they are only focused on investing in houses, apartments and commercial properties such as offices and malls, that is not necessarily always the case. For example, the Pacer Benchmark Data & Infrastructure Real Estate SCTR ETF (NYSEARCA: SRVR) is a REIT that tracks an index of companies that derive at least 85% of their earnings from real estate properties related to data and infrastructure, including the storage, computation and transmission of data.

In comparison to many other exchange-traded funds, SRVR’s managers do not engage in any sort of complex calculations or use any fancy weighting systems to attempt to tease out winners. The only things that the mangers do is to weight the REITs by market capitalization and cap the largest names at 15%.

Currently, the fund’s top holdings include Crown Castle International Corp. (NYSE: CCI), Equinix, Inc. (NASDAQ: EQIX), American Tower Corp. (NYSE: AMT), CyrusOne Inc. (NASDAQ: CONE), Iron Mountain Inc. (NYSE: IRM), CoreSite Realty Corp. (NYSE: COR), SBA Communications Corp. (NASDAQ: SBAC) and Cellnex Telecom ADR (OTCMKTS: CLLNY).

This fund’s performance has been mixed, even when including the damage done by the COVID-19 pandemic. As of Nov. 23, SRVR has been down 0.29% over the past month and 1.59% for the past three months. However, it is currently up 14.59% year to date.

Chart courtesy of www.stockcharts.com

The fund has amassed $1.54 billion in assets under management and has an expense ratio of 0.60%.

In short, while SRVR does provide an investor with a way to profit from data-related REITs, this kind of ETF may not be appropriate for all portfolios. Thus, interested investors always should conduct their due diligence and decide whether the fund is suitable for their investing goals.

As always, I am happy to answer any of your questions about ETFs, so do not hesitate to send me an email. You just may see your question answered in a future ETF Talk.

The post Blending Data and Real Estate appeared first on Stock Investor.

Read More

Continue Reading

International

Modified mRNA Demonstrates 10-Fold Protein Production

Scientists at Hong Kong University of Science and Technology came up with a technique to increase the efficiency and potentially the efficacy of mRNA therapeutics….

Published

on

Scientists at Hong Kong University of Science and Technology came up with a technique to increase the efficiency and potentially the efficacy of mRNA therapeutics. mRNA molecules have what is called a poly-A tail, which is basically a string of adenine nucleotides at one end. These researchers discovered that by replacing some of these nucleotides in the mRNA tail with cytidine, a cytosine base with a ribose sugar attached, that they could enhance the resulting protein production of the mRNA and increase its stability and life-span. The technique could lead to more effective mRNA therapies and vaccines, potentially enabling clinicians to achieve similar or better effects with smaller doses.

mRNA therapies have come a long way in just the last few years. The COVID-19 pandemic has propelled this approach from an emerging technology to a mainstay of our vaccine response. The concept is elegant – deliver mRNA strands to the patient, and allow their own cellular machinery to produce the relevant protein that the strands code for. So far, so good – the approach, once considered unrealistic because of the fragility of mRNA, has proven to work very well, at least for COVID-19 vaccines.  

However, there is always room for improvement. One of the issues with current mRNA therapies is that they can require multiple rounds of dosing to create enough of the therapeutic protein to achieve the desired effect. Think of the multiple injections required for the COVID-19 vaccines. Creating mRNA therapies that can induce our cells to produce more protein would certainly be beneficial.

To address this limitation, these researchers have found a way to modify the poly-A tail of synthetic mRNA strands. They found that by replacing some of the adenosine in the mRNA tail with cytidine, they could drastically increase the amount of protein the resulting strands ended up producing when applied to human cells and in mice. This translated to 3-10 times as much protein when compared with unmodified mRNA.

The researchers hope that the approach can enhance the effectiveness and required dosing schedules for mRNA therapies.

“Increasing the protein production of synthetic mRNA is generally beneficial to all mRNA drugs and vaccines,” said Becki Kuang, a researcher involved in the study. “In collaboration with Sun Yat-Sen University, our team is now exploring the use of optimized tails for mRNA cancer vaccines on animal. We are also looking forward to collaborating with pharmaceutical companies to transfer this invention onto mRNA therapeutics and vaccines’ development pipelines to benefit society.”

See a short animation about the technology below.

Study in journal Molecular Therapy – Nucleic Acids: Cytidine-containing tails robustly enhance and prolong protein production of synthetic mRNA in cell and in vivo

Via: Hong Kong University of Science and Technology

Read More

Continue Reading

International

LIV Golf Expands to Courses Used By PGA Tour

LIV Golf announced three new venues to its 2023 calendar.
The post LIV Golf Expands to Courses Used By PGA Tour appeared first on Front Office Sports.

Published

on

LIV Golf is pushing further into the PGA Tour’s turf.

The Saudi Arabia-backed league announced three new venues for its 2023 season, all of which are used regularly by the PGA Tour or DP World Tour.

  • In February, LIV Golf will come to El Camaleón in Mexico’s Mayakoba resort area. The course, designed by Greg Norman prior to his role as LIV Golf CEO, was the PGA Tour’s first course in Latin America.
  • In April, LIV will travel to Sentosa in Singapore, which has hosted the Singapore Open.
  • In June, the tour will make its trip to Spain’s Real Club Valderrama, whose history includes the Ryder Cup and DP World Tour events.

LIV is also adding The Grange Golf Club in Adelaide, Australia, as it grows to 14 events next year.

The PGA Tour, which is under investigation by the Justice Department over antitrust concerns, hired lobbyist and major Republican fundraiser Jeff Miller to improve its standing in Washington.

PGA Tour Hires Top Republican Strategist Amid LIV Golf Clash

The PGA Tour could be seeking help on the antitrust front.
December 1, 2022

Bank Shots

LIV golfers Phil Mickelson and Sergio Garcia responded to Tiger Woods after the latter called for Norman’s ouster due to his pugilistic stance toward the PGA Tour.

“Greg Norman is our CEO, and we support him,” said Garcia. “We all wish we could come to an agreement. There are people who could have done wrong in both places, but it seems that there are only bad guys on one side.”

Mickelson responded to a comment by Woods that the PGA Tour had to take out a huge loan to survive past the pandemic by tweeting out financial information from the Tour’s public documents.

The post LIV Golf Expands to Courses Used By PGA Tour appeared first on Front Office Sports.

Read More

Continue Reading

International

XPeng stock rises 48% from a double-bottom pattern. Should you buy it?

Shares of XPeng Inc. (NYSE:XPEV) rose 48% on Thursday premarket after promising delivery outlook. XPeng posted 5,811 electric vehicle deliveries in November….

Published

on

Shares of XPeng Inc. (NYSE:XPEV) rose 48% on Thursday premarket after promising delivery outlook. XPeng posted 5,811 electric vehicle deliveries in November. Despite the number falling 63% from the prior year, it increased 14% from October. The increase in deliveries reflected the easing of Covid-19 rules, which have hit EV makers in China this year.

XPeng said it expects the deliveries to rise significantly in December 2022. The deliveries will be boosted by a ramp-up in the production of G9s. Analysts project up to 10,000 deliveries in December. The delivery outlook overshadowed a reported Q3 loss of $0.39. XPeng’s revenue, however, rose 19.3% to $959.2 million or £786 million. The positive stock market news and outlook boosted the outlook for XPEV, which is already down 80% YTD.

XPEV recovers above the MA amid a bullish RSI divergence

XPEV Chart by TradingView

On the daily chart, XPEV recovered above the 20-day and 50-day moving averages. It is for the first time that the stock is recovering above the moving averages since July. 

XPEV is also recovering from a double bottom that formed close to $6.2. A bullish RSI divergence also occurred towards $6.2. The level could prove to be the bottom price if XPEV maintains the recovery. The RSI reading of 60 indicates that XPEV is yet to reach overbought levels.

How attractive is XPEV?

This article finds investing in XPEV favourable in the short term. With the deliveries and outlook, XPEV could continue to rise. The levels around $12 and $14 should be watched.

It should be noted that Chinese car sales tend to pick up towards the end of the year. So, it is possible for XPEV to maintain gains in the medium term, with the expectation.

However, we consider the greater stock market risks still high. China also still needs to ease its strict Covid-19 policy further, and it could weigh the automakers.

The post XPeng stock rises 48% from a double-bottom pattern. Should you buy it? appeared first on Invezz.

Read More

Continue Reading

Trending